Talk track

Key Messages

  • Over 30% of lung resection patients have ≥3 comorbidities, which correlates with higher surgical bleeding risk, transfusion complications, and increased costs.1*
  • Mechanical methods are effective for point bleeding but may be inefficient or impractical for low-pressure, diffuse oozing—especially in friable tissue or anatomically complex areas.
  • VISTASEAL™ is comprised of thrombin and fibrinogen, VISTASEAL™ creates an adherent clot regardless of the patient’s coagulation status.2-4,7
  • VISTASEAL™ offers a faster setup than alternatives with pre-filled syringes and no warming required.†8
  • Allows quick control of bleeding and minimizes re-bleed risk.10,11
  • Flexible applicator tip enables access to hard-to-reach thoracic anatomy.

Detailed Talk Track

You mentioned many of your thoracic surgery patients have significant comorbidities. In fact, a retrospective study found that over 30% of lung resection patients had three or more comorbidities. This higher comorbidity burden is associated with an increased risk of surgical bleeding, higher rates of transfusion-related complications, and elevated bleeding-related costs.1* I noticed at the end of the case, you used sutures or clips to control persistent oozing. While mechanical closure can be effective for discrete bleeding points, many surgeons find it time-consuming and less efficient when addressing diffuse or low-pressure bleeding—especially when tissues are friable or anatomically challenging. I’d like to introduce VISTASEAL™, a fibrin sealant composed of human thrombin and fibrinogen. It forms a rapid, adherent, and durable clot directly at the site of application, independent of the patient’s coagulation profile.2-4,7 This makes it particularly useful for high-risk patients where traditional mechanical options might not be ideal. VISTASEAL™ also offers practical advantages in the OR. It has significantly fewer setup steps compared to alternatives†8, thanks to pre-filled syringes and no need for warming, allowing you to address nuisance bleeding more quickly and proceed with closure confidently—potentially reducing the risk of re-bleeding.10,11 Its flexible applicator tip is well-suited for accessing hard-to-reach areas in the thoracic cavity. Would you be open to evaluating VISTASEAL™ in your next few high-risk patients to see how it performs compared to your current approach?

References

*In a retrospective study of 304,074 patients using the premier healthcare database. Comorbidities measured by Elixhauser Comorbidity index.

†Based on number of set-up steps and thawing time required for VISTASEAL™ Dual Applicator vs competitors.

1. Danker W. Increasing Incremental Burden of Surgical Bleeding Associated with Multiple Comorbidities as Measured by the Elixhauser Comorbidity Index: A Retrospective Database Analysis. Society for the Advancement of Patient Blood Management, September 16, 2022. Ethicon, Inc.

2. Bjelovic M, Ayguasonosa J, Kim RD, et al. A prospective, randomized, phase III study to evaluate the efficacy and safety of fibrin sealant Grifols as an adjunct to hemostasis as compared to cellulose sheets in hepatic surgery resections. J Gastrointest Surg. 2018. 22:1939–1949.

3. Nenezic D, Ayguasonosa J, Menyhei G, et al. A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols as an adjunct to hemostasis compared with manual compression in vascular surgery. J Vasc Surg. 2019: doi.org_10.1016_j.jvs.2018.12.051.

4. Lakshman S, Aqua K, Stefanovic A, et al. A prospective, single blind, randomized, phase III study to evaluate and efficacy of fibrin sealant Grifols as an adjunct to hemostasis during soft tissue open surgery. J Invest Surg. 2018;DOI:10.1080_08941939.2018.1489917.

5. Chetter I, Stansby G, Sarralde JA, et al. A prospective, randomized, multicenter clinical trial on the safety and efficacy of a ready-to-use fibrin sealant as an adjunct to hemostasis during vascular surgery. Ann Vasc Surg. 2017;45:127–137.

6. Hunt BJ. Bleeding and coagulapathies in critical care. 2014. N Engl J Med;370:847-859.

7. VISTASEAL™ Fibrin Sealant (Human). Full Prescribing Information. Instituto Grifols, S.A.

8. Thawing time and set-up steps comparison between VISTASEAL, EVICEL, and TISSEEL. Report 100708726-Rev 2. August 28, 2019. Ethicon, Inc.

9. VISTASEAL™ Fibrin Sealant (Human). Instructions for Use. Ethicon, Inc.

10. Shander A, Kaplan LJ, Harris MT, et al. Topical hemostatic therapy in surgery: bridging the knowledge and practice gap. J Am Coll Surg. 2014;219(3):570-579

11. Vyas K, Saha S. Comparison of hemostatic agents used in vascular surgery. Expert Opin Biol. Ther. 2013;13(12):1663-1672.

CONFIDENTIAL. FOR INTERNAL USE ONLY. NOT FOR USE WITH ANY CUSTOMER OR FOR EXTERNAL DISTRIBUTION.

Close

Click for assets
VISTASEAL™ Resources